These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 22641540)

  • 1. Antiarrhythmic potential of aldosterone antagonists in atrial fibrillation.
    Dąbrowski R; Szwed H
    Cardiol J; 2012; 19(3):223-9. PubMed ID: 22641540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aldosterone-receptor antagonism as a potential therapeutic option for atrial fibrillation.
    Lendeckel U; Dobrev D; Goette A
    Br J Pharmacol; 2010 Apr; 159(8):1581-3. PubMed ID: 20388187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertension and ethnic group: eplerenone may have role in hypertension related atrial fibrillation.
    Jolobe OM
    BMJ; 2006 Apr; 332(7547):974. PubMed ID: 16627524
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of eplerenone on maintenance of sinus rhythm after catheter ablation in patients with long-standing persistent atrial fibrillation.
    Ito Y; Yamasaki H; Naruse Y; Yoshida K; Kaneshiro T; Murakoshi N; Igarashi M; Kuroki K; Machino T; Xu D; Kunugita F; Sekiguchi Y; Sato A; Tada H; Aonuma K
    Am J Cardiol; 2013 Apr; 111(7):1012-8. PubMed ID: 23340033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis.
    Liu T; Korantzopoulos P; Shao Q; Zhang Z; Letsas KP; Li G
    Europace; 2016 May; 18(5):672-8. PubMed ID: 26705563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eplerenone Reduces Atrial Fibrillation Burden Without Preventing Atrial Electrical Remodeling.
    Takemoto Y; Ramirez RJ; Kaur K; Salvador-Montañés O; Ponce-Balbuena D; Ramos-Mondragón R; Ennis SR; Guerrero-Serna G; Berenfeld O; Jalife J
    J Am Coll Cardiol; 2017 Dec; 70(23):2893-2905. PubMed ID: 29216985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy of potassium canreonate-canrenone in sinus rhythm restoration among patients with atrial fibrillation - a protocol of a pilot, randomized, double -blind, placebo-controlled study (CANREN-AF trial).
    Dąbrowski R; Syska P; Mączyńska J; Farkowski M; Sawicki S; Kubaszek-Kornatowska A; Michałek P; Kowalik I; Szwed H; Hryniewiecki T
    Trials; 2020 May; 21(1):397. PubMed ID: 32398047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of combined spironolactone-β-blocker ± enalapril treatment on occurrence of symptomatic atrial fibrillation episodes in patients with a history of paroxysmal atrial fibrillation (SPIR-AF study).
    Dabrowski R; Borowiec A; Smolis-Bak E; Kowalik I; Sosnowski C; Kraska A; Kazimierska B; Wozniak J; Zareba W; Szwed H
    Am J Cardiol; 2010 Dec; 106(11):1609-14. PubMed ID: 21094362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective aldosterone blockade with eplerenone in patients with congestive heart failure.
    Salam AM
    Expert Opin Investig Drugs; 2003 Aug; 12(8):1423-7. PubMed ID: 12882627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of the renin-angiotensin-aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: a systematic review and meta analysis of randomized controlled trials.
    Khatib R; Joseph P; Briel M; Yusuf S; Healey J
    Int J Cardiol; 2013 Apr; 165(1):17-24. PubMed ID: 22421406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of spironolactone on patients with atrial fibrillation and structural heart disease.
    Williams RS; deLemos JA; Dimas V; Reisch J; Hill JA; Naseem RH
    Clin Cardiol; 2011 Jul; 34(7):415-9. PubMed ID: 21674535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure.
    George J; Struthers AD
    Expert Opin Pharmacother; 2007 Dec; 8(17):3053-9. PubMed ID: 18001264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure.
    Adams KF
    Am J Health Syst Pharm; 2004 May; 61 Suppl 2():S4-13. PubMed ID: 15160833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New treatment option for heart failure patients: eplerenone.
    Southworth MR; Cavallari LH
    J Cardiovasc Nurs; 2004; 19(6):390-5. PubMed ID: 15529060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist.
    McMahon EG
    Curr Opin Pharmacol; 2001 Apr; 1(2):190-6. PubMed ID: 11714095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mineralocorticoid receptor antagonists, a class beyond spironolactone--Focus on the special pharmacologic properties of eplerenone.
    Seferovic PM; Pelliccia F; Zivkovic I; Ristic A; Lalic N; Seferovic J; Simeunovic D; Milinkovic I; Rosano G
    Int J Cardiol; 2015 Dec; 200():3-7. PubMed ID: 26404746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of aldosterone antagonists for preventing atrial fibrillation after cardiac surgery in patients with systolic heart failure: a retrospective study.
    Simopoulos V; Tagarakis G; Hatziefthimiou A; Skoularigis I; Triposkiadis F; Trantou V; Tsilimingas N; Aidonidis I
    Clin Res Cardiol; 2015 Jan; 104(1):31-7. PubMed ID: 25134923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eplerenone: selective aldosterone antagonism in management of cardiovascular and renal disease.
    Brennan BJ; Martin NE
    J Am Pharm Assoc (2003); 2004; 44(5):604-10; quiz 610-1. PubMed ID: 15496047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New treasures from old? EPHESUS. Eplerenome Post-AHI Heart Failure Efficacy and Survival Study.
    Pfeffer MA
    Cardiovasc Drugs Ther; 2001 Jan; 15(1):11-3. PubMed ID: 11504157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension.
    Pelliccia F; Rosano G; Patti G; Volterrani M; Greco C; Gaudio C
    Int J Cardiol; 2015 Dec; 200():8-11. PubMed ID: 25466561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.